Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response

Vaccine

Volumn 29, Issue 51, 2011, Pages 9431-9440

  Moraes, Mauro Pires ^a,b   Segundo, Fayna Diaz San ^a,c   Dias, Camila C ^a,c   Pena, Lindomar ^a,c,d   Grubman, Marvin J ^a  

^a PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^d VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

FMDV protein 2B; FMDV serotype O1 Campos; Foot and mouth disease virus; Replication defective human adenovirus vectored vaccines; T cell response

Indexed keywords

ADENOVIRUS VECTOR; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 2B; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FOOT AND MOUTH DISEASE; HUMAN; HUMAN CELL; IMMUNOGENICITY; PRIORITY JOURNAL; T LYMPHOCYTE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CATTLE; CATTLE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOMEGALOVIRUS; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; HEK293 CELLS; HUMANS; PROMOTER REGIONS, GENETIC; SWINE; T-LYMPHOCYTES; VACCINATION; VACCINES, SUBUNIT; VIRAL PROTEINS; VIRAL VACCINES;

EID: 81955161876     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.037     Document Type: Article

References (64)

1. Alexandersen S., Mowat N. Foot-and-mouth disease: host range and pathogenesis. Curr Top Microbiol Immunol 2005, 288:9-42.
2. Kitching R.P. A recent history of foot-and-mouth disease. J Comp Pathol 1998, 118(2):89-108.
3. Kitching P., Hammond J., Jeggo M., Charleston B., Paton D., Rodriguez L., et al. Global FMD control - is it an option?. Vaccine 2007, 25(30):5660-5664.
4. Grubman M.J., Baxt B. Foot-and-mouth disease. Clin Microbiol Rev 2004, 17(2):465-493.
5. Grubman M.J., Morgan D.O., Kendall J., Baxt B. Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells. J Virol 1985, 56(1):120-126.
6. Knowles N.J., Samuel A.R. Molecular epidemiology of foot-and-mouth disease virus. Virus Res 2003, 91(1):65-80.
7. Nishina H., Omori C. An epidemiological analysis of the foot-and-mouth disease epidemic in Miyazaki, Japan. Transbound Emerg Dis 2010, 57:396-403.
8. Paton D.J., King D.P., Knowles N.J., Hammond J. Recent spread of foot-and-mouth disease in the Far East. Vet Rec 2010, 166:569-570.
9. OIE. Terrestrial Animal Health Code. Chapter 2.2.10. Foot and mouth disease. Article 2.2.10.8. Recovery of free status; 2007.
10. Grubman M.J. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Biologicals 2005, 33:227-234.
11. Doel T.R. FMD vaccines. Virus Res 2003, 91(1):81-99.
12. Salt J.S. The carrier state in foot and mouth disease - an immunological review. Br Vet J 1993, 149(3):207-223.
13. Barteling S.J., Vreeswijk J. Developments in foot-and-mouth disease vaccines. Vaccine 1991, 9(2):75-88.
14. DEFRA. Department for environment, food and rural affairs. Final epidemiological report; 2007. Available from: http://archive.defra.gov.uk/foodfarm/farmanimal/diseases/atoz/fmd/2007/index.htm.
15. Rodriguez L.L., Grubman M.J. Foot and mouth disease virus vaccines. Vaccine 2009, 27(Suppl. 4):D90-D94.
16. Collen T., Pullen L., Doel T.R. T cell-dependent induction of antibody against foot-and-mouth disease virus in a mouse model. J Gen Virol 1989, 70(Pt 2):395-403.
17. Salt J.S., Barnett P.V., Dani P., Williams L. Emergency vaccination of pigs against foot-and-mouth disease: protection against disease and reduction in contact transmission. Vaccine 1998, 16(7):746-754.
18. McCullough K.C., Bruckner L., Schaffner R., Fraefel W., Muller H.K., Kihm U. Relationship between the anti-FMD virus antibody reaction as measured by different assays, and protection in vivo against challenge infection. Vet Microbiol 1992, 30(2-3):99-112.
19. Sobrino F., Saiz M., Jimenez-Clavero M.A., Nunez J.I., Rosas M.F., Baranowski E., et al. Foot-and-mouth disease virus: a long known virus, but a current threat. Vet Res 2001, 32(1):1-30.
20. Collen T., Baron J., Childerstone A., Corteyn A., Doel T.R., Flint M., et al. Heterotypic recognition of recombinant FMDV proteins by bovine T-cells: the polymerase (P3Dpol) as an immunodominant T-cell immunogen. Virus Res 1998, 56(2):125-133.
21. van Lierop M.J., van Maanen K., Meloen R.H., Rutten V.P., de Jong M.A., Hensen E.J. Proliferative lymphocyte responses to foot-and-mouth disease virus and three FMDV peptides after vaccination or immunization with these peptides in cattle. Immunology 1992, 75(3):406-413.
22. Blanco E., Garcia-Briones M., Sanz-Parra A., Gomes P., De Oliveira E., Valero M.L., et al. Identification of T-cell epitopes in nonstructural proteins of foot-and-mouth disease virus. J Virol 2001, 75(7):3164-3174.
23. + T-cell response is induced in cattle by foot-and-mouth disease virus (FMDV) infection and also following vaccination with inactivated FMDV. J Gen Virol 2008, 89(Pt 3):667-675.
24. Rodriguez L.L., Barrera J., Kramer E., Lubroth J., Brown F., Golde W.T. A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type-O VP1 and a promiscuous T-helper epitope induces peptide-specific antibodies but fails to protect cattle against viral challenge. Vaccine 2003, 21(25-26):3751-3756.
25. Sanz-Parra A., Jimenez-Clavero M.A., Garcia-Briones M.M., Blanco E., Sobrino F., Ley V. Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs. Virology 1999, 259(1):129-134.
26. Garcia-Briones M.M., Blanco E., Chiva C., Andreu D., Ley V., Sobrino F. Immunogenicity and T cell recognition in swine of foot-and-mouth disease virus polymerase 3D. Virology 2004, 322(2):264-275.
27. Taboga O., Tami C., Carrillo E., Nunez J.I., Rodriguez A., Saiz J.C., et al. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J Virol 1997, 71(4):2606-2614.
28. Grubman M.J., Moraes M.P., Schutta C., Barrera J., Neilan J., Ettyreddy D., et al. Adenovirus serotype 5-vectored foot-and-mouth disease subunit vaccines: the first decade. Future Virol 2010, 5(1):51-64.
29. Moraes M.P., Mayr G.A., Mason P.W., Grubman M.J. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 2002, 20(11-12):1631-11639.
30. Pacheco J.M., Brum M.C., Moraes M.P., Golde W.T., Grubman M.J. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology 2005, 337(2):205-209.
31. Doel T.R., Williams L., Barnett P.V. Emergency vaccination against foot-and-mouth disease: rate of development of immunity and its implications for the carrier state. Vaccine 1994, 12(7):592-600.
32. Pay T.W., Hingley P.J. Correlation of 140S antigen dose with the serum neutralizing antibody response and the level of protection induced in cattle by foot-and-mouth disease vaccines. Vaccine 1987, 5(1):60-64.
33. Caron L., Brum M.C.S., Moraes M.P., Golde W.T., Arns C.W., Grubman M.J. Granulocyte-machrophage colony-stimulating factor does not increase the potency or efficacy of a foot-and-mouth disease virus subunit vaccine. Pesq Vet Bras 2005, 23(3):150-158.
34. Pena L., Moraes M.P., Koster M., Burrage T., Pacheco J.M., Diaz-San Segundo F., et al. Delivery of a foot-and-mouth disease virus empty capsid subunit antigen with nonstructural protein 2B improves protection of swine. Vaccine 2008, 26(45):5689-5699.
35. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977, 36(1):59-74.
36. Bautista D.S., Hitt M., McGrory J., Graham F.L. Isolation and characterization of insertion mutants in E1A of adenovirus type 5. Virology 1991, 182(2):578-596.
37. Moraes M.P., Mayr G.A., Grubman M.J. pAd5-Blue: direct ligation system for engineering recombinant adenovirus constructs. Biotechniques 2001, 31(5):1050-1056.
38. Moraes M.P., de los Santos T., Koster M., Turecek T., Wang H., Andreyev V.G., et al. Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons. J Virol 2007, 81(13):7124-7135.
39. Rieder E., Bunch T., Brown F., Mason P.W. Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice. J Virol 1993, 67(9):5139-5145.
40. Wu Q., Moraes M.P., Grubman M.J. Recombinant adenovirus co-expressing capsid proteins of two serotypes of foot-and-mouth disease virus (FMDV): in vitro characterization and induction of neutralizing antibodies against FMDV in swine. Virus Res 2003, 93(2):211-219.
41. Mayr G.A., Chinsangaram J., Grubman M.J. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 1999, 263(2):496-506.
42. Mayr G.A., O'Donnell V., Chinsangaram J., Mason P.W., Grubman M.J. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine 2001, 19(15-16):2152-2162.
43. Moraes M.P., Chinsangaram J., Brum M.C., Grubman M.J. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine 2003, 22(2):268-279.
44. de Avila Botton S., Brum M.C., Bautista E., Koster M., Weiblen R., Golde W.T., et al. Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine 2006, 24(17):3446-3456.
45. Valarcher J.F., Knowles N.J., Zakharov V., Scherbakov A., Zhang Z., Shang Y.J., et al. Multiple origins of foot-and-mouth disease virus serotype Asia 1 outbreaks, 2003-2007. Emerg Infect Dis 2009, 15(7):1046-1051.
46. + T cells by DNA vaccination depends on appropriate targeting of sufficient levels of immunologically relevant antigen to appropriate processing pathways. J Immunol 2002, 169(9):4951-4960.
47. + T lymphocytes. J Immunol 2007, 179(10):6725-6733.
48. + T cells. J Virol 2007, 81(23):12793-12802.
49. Patch J.R., Pedersen L.E., Toka F.N., Moraes M., Grubman M.J., Nielsen M., et al. Induction of foot-and-mouth disease virus-specific cytotoxic T cell killing by vaccination. Clin Vaccine Immunol 2011, 18(2):280-288.
50. Bautista E.M., Ferman G.S., Golde W.T. Induction of lymphopenia and inhibition of T cell function during acute infection of swine with foot-and-mouth disease virus (FMDV). Vet Immunol Immunopathol 2003, 92:61-73.
51. Guzylack-Piriou L., Bergamin F., Gerber M., McCullough K.C., Summerfield A. Plasmacytoid dendritic cell activation by foot-and-mouth disease virus requires immune complexes. Eur J Immunol 2006, 36:1674-1683.
52. Diaz-San Segundo F., Salguero F.J., de Avila A., de Marco M.M., Sanchez-Martin M.A., Sevilla N. Selective lymphocyte depletion during the early stage of the immune response to foot-and-mouth disease virus infection in swine. J Virol 2006, 80(5):2369-2379.
53. Golde W.T., Nfon C.K., Toka F.N. Immune evasion during foot-and-mouth disease virus infection of swine. Immunol Rev 2008, 225:85-95.
54. Nfon C.K., Ferman G.S., Toka F.N., Gregg D.A., Golde W.T. Interferon-alpha production by swine dendritic cells is inhibited during acute infection with foot-and-mouth disease virus. Viral Immunol 2008, 21(1):68-77.
55. Toka F.N., Nfon C., Dawson H., Golde W.T. Natural killer cell dysfunction during acute infection with foot-and-mouth disease virus. Clin Vaccine Immunol 2009, 16(12):1738-1749.
56. Toka F.N., Nfon C.K., Dawson H., Estes D.M., Golde W.T. Activation of porcine natural killer cells and lysis of foot-and-mouth disease virus infected cells. J Int Cyt Res 2009, 29(3):179-192.
57. Diaz-San Segundo F., Rodriguez-Calvo T., de Avila A., Sevilla N. Immunosuppression during acute infection with foot-and-mouth disease virus in swine is mediated by IL-10. PLoS One 2009, 4(5):e5659.
58. + T-cell responses to foot-and-mouth disease virus. J Gen Virol 1999, 80(Pt 3):663-669.
59. Garcia-Valcarcel M., Doel T., Collen T., Ryan M., Parkhouse R.M. Recognition of foot-and-mouth disease virus and its capsid protein VP1 by bovine peripheral T lymphocytes. J Gen Virol 1996, 77(Pt 4):727-735.
60. Parida S., Oh Y., Reid S.M., Cox S.J., Statham R.J., Mahapatra M., et al. Interferon-gamma production in vitro from whole blood of foot-and-mouth disease virus (FMDV) vaccinated and infected cattle after incubation with inactivated FMDV. Vaccine 2006, 24(7):964-969.
61. Sanz-Parra A., Vazquez B., Sobrino F., Cox S.J., Ley V., Salt J.S. Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins. J Gen Virol 1999, 80(Pt 3):671-679.
62. Maeda K., West K., Hayasaka D., Ennis F.A., Terajima M. Recombinant adenovirus vector vaccine induces stronger cytotoxic T-cell responses than recombinant vaccinia virus vector, plasmid DNA, or a combination of these. Viral Immunol 2005, 18(4):657-667.
63. Zhang Z.D., Hutching G., Kitching P., Alexandersen S. The effects of gamma interferon on replication of foot-and-mouth disease virus in persistently infected bovine cells. Arch Virol 2002, 147(11):2157-2167.
64. Cedillo-Barron L., Foster-Cuevas M., Cook A., Gutierrez-Castaneda B., Kollnberger S., Lefevre F., et al. Immunogenicity of plasmids encoding T and B cell epitopes of foot-and-mouth disease virus (FMDV) in swine. Vaccine 2003, 21(27-30):4261-4269.